Tuesday | Wednesday | Thursday | Friday | Saturday
THURSDAY, DECEMBER 12, 2019
     
6:45 am - 5:15 pm Registration - Main Lobby  
     
7:00 am - 9:00 am SPOTLIGHT SESSION 4: Targeting HER2 and DNA Repair - Stars at Night Ballroom 1&2 - 3rd Level
Chair: Ian Krop, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Discussants                         

DNA repair
Jennifer Litton, MD
UT MD Anderson Cancer Center
Houston, TX

HER2
Antonio Wolff, MD, FACP, FASCO
Johns Hopkins School of Medicine
Baltimore, MD
 
     
7:00 am - 9:00 am SPOTLIGHT SESSION 5: Immunooncology Biomarkers and the Immune Landscape of Breast Cancer - Stars at Night Ballroom 3&4 - 3rd Level
Chair: Heather McArthur, MD, MPH
Cedars-Sinai
Samuel Oschin Comprehensive Cancer Institute
Los Angeles, CA

Discussants:

IO/PDL1
Ashley Cimino-Mathews, MD
Johns Hopkins University School of Medicine
Baltimore, MD

TILs/Clinical correlatatives
Heather McArthur, MD, MPH
Cedars-Sinai
Samuel Oschin Comprehensive Cancer Institute
Los Angeles, CA
 
     
7:00 am - 9:00 am

POSTER SESSION 2 & continental breakfast - Hall 1

 
 

Detection/Diagnosis

 
 

Imaging and Screening - Radiology - Tumor Monitoring
Imaging and Screening - Screening
Other

P2-01
P2-02
P2-03

                           Tumor Cell and Molecular Biology  
 

Cellular Mechanisms
DNA Damage and Repair
Stem/Progenitor Cells
Growth Factors

P2-04
P2-05
P2-06
P2-07

  Epidemiology, Risk, and Prevention  
  Population Studies
Genetic and Molecular
Ethnic/Racial Aspects
P2-08
P2-09
P2-10
     
  Prognostic and Predictive Factors  
  Biomarkers Predicting Treatment Sensitivity and Resistance - Predictive Biomarkers for Endocrine Therapies
P2-11
     
  Psychosocial, Quality of Life, and Educational Aspects  
  Supportive Care
Survivorship Research
P2-12
P2-13

   
  Treatment  
  Adjuvant Therapy - Adjuvant Chemotherapy
Advanced Disease Treatment - Advanced Chemotherapy
Therapeutic Strategies - Neoadjuvant Chemotherapy
Advanced Disease Treatment - Advanced Therapy - Other
Adjuvant Therapy - Other
Types and Sites of Breast Cancer - Bone Metastases
Types and Sites of Breast Cancer - Brain Metastases
Research Resources - Tissue and Data Banks
P2-14
P2-15
P2-16
P2-17
P2-18
P2-19
P2-20
P2-21
     
9:00 am - 9:30 am PLENARY LECTURE 2 – Hall 3  
 

The Role of Radiotherapy Combined With Immunotherapy in Oligometastatic Cancer
Ralph R. Weichselbaum, MD
University of Chicago
Chicago, IL

 
     
9:30 am - 11:30 am

GENERAL SESSION 3 – Hall 3
Moderator: TBD

 
     
9:30 am

GS3-01. Keynote-522 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer: Pathologic complete response in key subgroups

 
                           Schmid P.  Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
 
9:45 am

GS3-02. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study

 
  Gianni L, Huang C, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Bianchini G, Russo S, Ciruelos E, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Maffeis I, Valagussa P, Viale G. Fondazione Michelangelo, Milano, Italy; National Taiwan University Hospital and Taiwan Breast Cancer Consortium, Taipei, Taiwan; BrustGesundheitZentrum Tirol, Medical University Innsbruck, Innsbruck, Austria; Hospital Clinico Universitario, Valencia, Spain; Policlinico S. Orsola Malpighi SSD Oncologia Medica Addarii, Bologna, Italy; Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany; Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain; San Raffaele Hospital, Milano, Italy; Ospedale Santa Maria della Misericordia, Udine, Italy; Hospital Universitario 12 de Octubre, Madrid, Spain; Paracelsus Medical University Salzburg; Salzburg Cancer and Cancer cluster, Salzburg, Austria; NN Petrov Research Inst of Oncology, St Petersburg, Russian Federation; Istituto Europeo di Oncologia, Milano, Italy; Cancer Trials Ireland & Mater Misericordiae University Hospital, Dublin, Ireland; IRCCS Istituto Nazionale Tumori, Milano, Italy; Università degli Studi di Genova, Ospedale Policlinico San Martino, Genova, Italy.
 
10:00 am

GS3-03.  TBD

 
10:15 am

GS3-04.  Discussant
Kevin Kalinsky, MD, MS
Columbia University Irving Medical Center
New York, NY

 
10:30 am

GS3-05.  The genomic landscape of breast cancer based on ctDNA analysis: data from the plasmaMATCH trial

 
  Kingston B, Bye H, Hubank M, Walsh G, Swift C, Beaney M, Kilburn L, Kernaghan S, Wardley AM, Macpherson I, Baird RD, Roylance R, Wilkinson K, Garcia-Murillas I, Bliss JM, Turner N, Ring A, on behalf of the plasmaMATCH Trial Management Group. The Institute of Cancer Research, London, United Kingdom; The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; The Royal Marsden NHS Foundation Trust, Sutton and The Institute of Cancer Research, London, United Kingdom; Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom; The NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust and Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine & Health, University of Manchester, Manchester, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Cancer Research UK Cambridge Centre, Cambridge, United Kingdom; University College London Hospitals NHS Foundation Trust, and NIHR University College London Hospitals Biomedical Research Centre, London, United Kingdom; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom.  
10:45 am

GS3-06.  Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)

 
  Turner N, Kingston B, Kilburn L, Kernaghan S, Wardley AM, Macpherson I, Baird RD, Roylance R, Stephens P, Oikonomidou O, Braybrooke JP, Tuthill M, Abraham J, Winter MC, Bye H, Hubank M, Snowdon C, Rea D, Cameron D, Shaaban A, Randle K, Wilkinson K, Moretti L, Bliss JM, Ring A, on behalf of the plasmaMATCH Trial Management Group.  The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom; Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom; The NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust and Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Manchester, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Cancer Research UK Cambridge Centre, Cambridge, United Kingdom; University College London Hospitals NHS Foundation Trust and NIHR University College London Hospitals Biomedical Research Centre, London, United Kingdom; Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom; Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom; University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; Velindre University NHS Trust, Cardiff, United Kingdom; Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; The Royal Marsden NHS Foundation Trust, Sutton and The Institute of Cancer Research, London, United Kingdom; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; Independent Cancer Patients' Voice, London, United Kingdom.  
11:00 am

GS3-07.  Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network

 
                           King TA, Liu MC, McClure MB, Hinoue T, Kelly BJ, Creighton CJ, Bowen J, Leraas K, Burns RT, Coppens S, Rezk S, Garrett AL, Balko JM, Parker JS, Park BH, Krop I, Anders C, Hoadley KA, Gastier-Foster J, Rimawi MF, Nanda R, Lin NU, Isaacs C, Marcom P, Storniolo A, Couch FJ, Mardis ER, Lee AV, Chandran U, Laird PW, Hilsenbeck SG, Norton L, Richardson AL, Symmans W, Carey LA, Wolff AC, Davidson NE, Perou CM, the AURORA US Network. Dana Farber Cancer Institute, Boston, MA; Mayo Clinic, Rochester, MN; University of North Carolina, Chapel Hill, NC; Van Andel Research Institute, Grand Rapids, MI; Nationwide Children’s Hospital, Columbus, OH; Baylor College of Medicine, Houston, TX; Translational Breast Cancer Research Consortium, Baltimore, MD; Vanderbilt University Medical Center, Nashville, TN; Duke University, Durham, NC; University of Chicago, Chicago, IL; Georgetown University, Washington DC, DC; Indiana University School of Medicine, Indianapolis, IN; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Johns Hopkins University, Baltimore, MD; MD Anderson Cancer Center, Houston, TX; Fred Hutchinson Cancer Research Center, Seattle, WA.  
11:15 am

GS3-08.  TBD

 
     
10:45 am - 5:00 pm EXHIBITS - Hall 2  
     
11:30 am - 12:00 pm

AACR  DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH - Hall 3

 
       Essential Genes and Cistromes in Breast Cancer
Myles Brown, MD
Dana-Farber Cancer Institute
Boston, MA

     
12:00 pm - 1:00 pm  BREAK  
     
12:00 pm - 1:00 pm  CAREER DEVELOPMENT FORUM - Room 304 
 
  Panel Q&A: Getting the Most from Your Training
A distinguished panel of researchers will answer questions from the audience and provide advice for a candid view into the skills, work, and resources needed for a productive and fulfilling traineeship.  Panelists represent the spectrum of basic to clinical researchers, ensuring that students, postdoctoral fellows and medical residents alike receive valuable insight on their fellowships.  Please join us for an inside look into how to get the most from your training!

Panelists:

E. Shelley Hwang, MD, MPH
Duke Cancer Institute
Durham, NC

Geoffrey Wahl, PhD
The Salk Institute for Biological Studies
La Jolla, CA

Alana L. Welm, PhD
University of Utah Huntsman Cancer Institute
Salt Lake City, UT

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA
 
     
1:00 pm - 2:00 pm

CASE DISCUSSION 1 – Stars at Night Ballroom 1&2 - 3rd Level

 
  Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Panelists: 

Tari A. King, MD
Dana-Farber Cancer Center
Boston, MA

Pierfranco Conte, MD
University of Padova
Padova, ITALY

Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN

Benjamin Smith, MD
UT MD Anderson Cancer Center
Houston, TX

Medha Deoras-Sutliff
The US EHE Foundation
Newark, OH

 
      

1:00 pm - 2:00 pm TRANSLATIONAL SCIENCE FORUM 1 - Stars at Night Ballroom 3&4 - 3rd Level  
 

Proteogenomics of Breast Cancer, from Discovery to Precision Medicine
Moderator: Matthew J. Ellis, MD, BChir, BSc, PhD FRCP
Baylor College of Medicine
Lester & Sue Smith Breast Center
Houston, TX

Advanced enabling technologies for cancer proteomics
Tao Liu, PhD
Pacific Northwest National Laboratory
Richland, WA

Proteogenomic landscape of prospectively collected breast cancer
Michael Gillette, MD, PhD
Broad Institute
Cambridge, MA

Proteogenomics and clinical translation
Matthew J. Ellis, MB, BChir, BSc, PhD, FRCP
Baylor College of Medicine
Houston, TX

 
     
2:15 pm - 3:15 pm MINI-SYMPOSIUM 1 - Hall 3  
 

Future of Immuno-oncology in Breast Cancer
Moderators:
Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX
and 
Helen Heslop, MBChB, MD, DSc
Baylor College of Medicine
Houston, TX

Immunotherapy in breast cancer: enhancing response to checkpoint blockade
Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Cancer Institute
Brigham and Women's Cancer Center
Boston, MA

T cell-based immunotherapy for a "public" neoantigen derived from a PIK3CA hotspot mutation
Christopher A. Klebanoff, MD
Memorial Sloan Kettering Cancer Center
New York, NY

 
     
3:15 pm - 5:00 pm

GENERAL SESSION 4 – Hall 3
Moderator: TBD

 
     
3:15 pm

GS4-01. Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI)

 
  Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL III, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N. NRG Oncology, and Orlando Health UF Health Cancer Center, Orlando, FL; NRG Oncology, and University of Pittsburgh, Pittsburgh, PA; NRG Oncology, and Virginia Commonwealth University School of Medicine Massey Cancer Center, Richmond, VA; NRG Oncology, and Kaiser Permanente Oncology Clinical Trials Northern, Novato, CA; NRG Oncology, and Waverly Hematology Oncology, Cary, NC; NRG Oncology, and British Columbia Cancer Agency, Vancouver, BC, Canada; NRG Oncology, and University of Pittsburgh, Magee-Womens Hospital, Pittsburgh, PA; Cancer Trials Ireland (Formerly known as Irish Clinical Oncology Research Group – ICORG), Dublin, Ireland; NRG Oncology, and Florida Cancer Specialists, Fort Myers, FL; NRG Oncology, and CCOP Wichita via Christi Reg. Med. Ctr., Wichita, KS; NRG Oncology, and Atlanta Cancer Care, Atlanta, GA; NRG Oncology, and Decatur Memorial Hospital/Cancer Care Specialists of Illinois/Heartland NCORP, Decatur, IL; NRG Oncology, and Medstar Franklin Square Medical Center, Baltimore, MD; NRG Oncology, and Yonsei University College of Medicine, Seoul, Korea, Republic of; NRG Oncology, and Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; NSABP/NRG Oncology, Pittsburgh, PA.  
3:30 pm

GS4-02. Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database

 
  Pan H, Braybrooke J, Gray R, Peto R, Bradley R, Hills R, Bergh J, Swain SM, Dowsett M, Hayes DF, Gelber RD, for the EBCTCG.  Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Dept of Oncology-Pathology, Karolinska Institutet and the Breast Cancer Centre, Karolinska University Hospital, Stockholm, Sweden; Georgetown University Medical Center, Washington DC, DC; Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.  
3:45 pm

GS4-03. Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study

 
  Sestak I, Crager M, Cuzick J, Dowsett M, Shak S, Tang G, Gray R, Sparano J.  Centre for Cancer Prevention, London, United Kingdom; Genomic Health, Redwood City, CA; Ralph Lauren Centre for Breast Cancer Research, London, United Kingdom; University of Pittsburgh, Pittsburgh, PA; Dana Farber Cancer Institute, Boston, MA; Albert Einstein College of Medicine, New York, NY.  
4:00 pm

GS4-04. Ten year results of the international breast cancer intervention study II

 
  Cuzick J, Sestak I, Forbes J, Dowsett M, Cawthorn S, Mansell R, Loibl S, Bonanni B, Howell A, IBIS-II investigators. Centre for Cancer Prevention, London, United Kingdom; School of Medicine and Public Health, Newcastle, Australia; Ralph Lauren Centre for Breast Cancer Research, London, United Kingdom; North Bristol NHS Trust, Bristol, United Kingdom; Cardiff University, Cardiff, United Kingdom; German Breast Group, Frankfurt, Germany; Istituto Europeo di Oncologia, Milan, Italy; University of Manchester, Manchester, United Kingdom.
 
4:15 pm  GS4-05. Should age be integrated together with clinical and genomic risk for adjuvant chemotherapy decision in early luminal breast cancer? MINDACT results compared to those of TAILOR-X
 
  To be presented by Fatima Cardoso
Piccart MJ, Poncet C, Cardoso F, van't Veer L, Delaloge S, Pierga J, Brain E, Vrijaldenhoven S, Neijenhuis P, Aalders K, Rutgers E. Institute Jules Bordet, Université Libre de Belgique, Brussels, Belgium; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal; University California San Francisco, San Francisco, CA; Gustave Roussy, Unicancer Breast Group UCBG, Villejuif, France; Institut Curie Paris & St Cloud, Université Paris Descartes, Paris, France; Institut Curie - Hôpital Rene Huguenin, Saint Cloud, France; Noordwest Ziekenhuisgroep - Site Alkmaar, Alkmaar, Netherlands; Rijnland Ziekenhuis-Alrijne Zorgroep, Leiderdop, Netherlands; Gelre Hospital, Apeldoorn, Netherlands; Netherlands Cancer Institute, Amsterdam, Netherlands.
 
4:30 pm

GS4-06. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial

 
  Meattini I, Saieva C, Lucidi S, lo Russo M, Scotti V, Desideri I, Marrazzo L, Simontacchi G, Mangoni M, Becherini C, Visani L, Paoletti L, Moretti E, Triggiani L, Bernini M, Orzalesi L, Sanchez L, Nori J, Pallotta S, Bianchi S, Livi L. University of Florence, Florence, Italy; Istituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO), Florence, Italy; Ospedale Santa Maria Annunziata - Azienda Usl Toscana centro, Florence, Italy; Ospedale S. Stefano - Azienda Usl Toscana centro, Prato, Italy; University of Brescia, Brescia, Italy.  
 4:45 pm GS4-07. Costs and effects in the first randomized trial comparing MRI breast cancer screening with mammography in women with a familial risk: FaMRIsc 
 
  Tilanus-Linthorst MMA, Geuzinge HA, Obdeijn IM, Rutgers EJT, Mann RM, Saadatmand S, de Roy van Zuidewijn DBW, Tollenaar RAEM, Lobbes MBI, Ausems MGEM, van 't Riet M, Hooning MJ, Wesseling J, Mares-Engelberts I, Luiten EJT, Oosterwijk JC, Heijnsdijk EAM, de Koning HJ. Erasmus University MC, Rotterdam, Netherlands; The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Radboud University Hospital, Nijmegen, Netherlands; Medical Center Leeuwarden, Leeuwarden, Netherlands; Leiden University MC, Leiden, Netherlands; Academic Hospital Maastricht, Maastricht, Netherlands; University MC Utrecht, Utrecht, Netherlands; Reinier de Graaf Gasthuis, Delft, Netherlands; Vlietland Ziekenhuis, Schiedam, Netherlands; Amphia Ziekenhuis, Breda, Netherlands; University MC Groningen, Groningen, Netherlands.  
 
 
5:00 pm - 7:00 pm

SPOTLIGHT SESSION 6: Local Regional Therapy/DCIS – Hemisfair Ballroom - 3rd Level

Chair: Karen Hoffman, MD
UT MD Anderson Cancer Center
Houston, TX

Discussants:

Surgery
Andrea Barrio, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY

Radiation
Karen Hoffman, MD
UT MD Anderson Cancer Center
Houston, TX

DCIS
Fariba Behbod, Pharm.D., PhD
University of Kansas
Kansas City, KS

 
     
 5:00 pm - 7:00 pm SPOTLIGHT SESSION 7: The Science of ER Resistance and Emerging Clinical Strategies - Stars at Night Ballroom 1&2 - 3rd Level

Chair: Stacy Moulder, MD
UT MD Anderson Cancer Center
Houston, TX

Discussants:

Science of ER resistance
David Cescon, MD
Princess Margaret Cancer Centre
Toronto, CANADA

Novel drugs for ER metastasis
Rachel M. Layman, MD
UT MD Anderson Cancer Center
Houston, TX
 
     
5:00 pm - 7:00 pm  SPOTLIGHT SESSION 8: The Metastatic Landscape - Drug Resistance and Metastasis Biology - Stars at Night Ballroom 3&4 - 3rd Level  
  Chair: Alana Welm, PhD
University of Utah Huntsman Cancer Institute
Salt Lake City, UT

Discussants:

Genomic studies in metastasis
Alana Welm, PhD
University of Utah Huntsman Cancer Institute
Salt Lake City, UT

Metastasis biology
Shridar Ganesan, MD, PhD
Rutgers Cancer Institute
New Brunswick, NJ
 
     
5:00 pm - 7:00 pm POSTER SESSION 3 & reception – Hall 1
                             
  Tumor Cell and Molecular Biology  

Tumor Progression, Invasion, and Metastasis
Metabolism and Breast Cancer
Signaling Pathways
Telomeres/Telomerase
Other
Novel/Emerging Therapeutic Targets

P3-01
P3-02
P3-03
P3-04
P3-05
P3-06

 
 
 

Prognostic and Predictive Factors

Prognostic Factors - Prognostic Factor Index Scores
Other

P3-07
P3-08

     
 

Treatment

Therapeutic Strategies - Immunotherapy (Clinical)                                                                                                                                                                                          
Therapeutic Strategies - Novel Targets and Targeted Agents
Therapeutic Strategies - New Drug and Treatment Strategies
Therapeutic Strategies - Antiangiogenic Therapy (Adjuvant and Metastatic)
Therapeutic Strategies - Signal Transduction Inhibitors
Adjuvant Therapy - Targeted

P3-09
P3-10
P3-11
P3-12
P3-13
P3-14



 
  Ongoing Trials

Targeted - HER2
Targeted - CDK4/6
Targeted - PARP
Targeted - PD-1/PD-L1
Targeted - VEGFR
Targeted - PI3K
Targeted - FGFR
Targeted - AKT
Targeted - Microtubules
 

OT2-01
OT2-02
OT2-03
OT2-04
OT2-05
OT2-06
OT2-07
OT2-08
OT2-09
     
 7:30 pm OPEN SATELLITE EVENT presented by Harborside Medical Education - Marriott Rivercenter

Breast Cancer Brain Metastases: Key Strategies for Optimal Management 

For further information and to register for this event, visit https://www.eventbrite.com/e/breast-cancer-brain-metastases-key-strategies-for-optimal-management-registration-71692294583

 
     
7:30 pm OPEN SATELLITE EVENT presented by Research to Practice - Marriott Rivercenter, Grand Ballroom G-M

Data + Perspectives: Clinical Investigators Explore the Current and Future Management of Triple-Negative Breast Cancer

For further information and to register for this event, visit
http://www.researchtopractice.com/Meetings/SA2019
 
 
Tuesday | Wednesday | Thursday | Friday | Saturday